Article Information
History
- February 18, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Juan Pablo Diaz Martinez1,*,
- Therese Aubry de Maraumont2,
- Elly Natty Sánchez2,
- Luis Miguel Camacho Cordero2 and
- Eric Yeh3
- 1Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada;
- 2Health Economics Amgen Mexico, Mexico City, Mexico
- 3Health Economics Amgen
- ↵*Corresponding author: juan.diaz.martinez{at}mail.utoronto.ca (JPDM)
Posted February 18, 2024.
Cost-effectiveness of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico
